Physician profile
Herman Ronald Clements
NPI 1427019371
$186,809.21
in general payments reported to CMS, 2019-2025
23 companies · $52K in 2025
The $52K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,695 · 2020: $22K · 2021: $38K · 2022: $14K · 2023: $24K · 2024: $32K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Honoraria: $20K · Travel and Lodging: $6,964 · Food and Beverage: $5,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,600.00 |
| Honoraria | $20,400.00 |
| Travel and Lodging | $6,964.28 |
| Food and Beverage | $5,700.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116,479.09 | 2021-2025 | Vraylar |
| Allergan, INC. | $30,211.04 | 2019-2021 | |
| Tris Pharma INC | $27,219.08 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $8,103.58 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $951.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $680.01 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $602.03 | 2019-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $373.76 | 2021-2025 | Uzedy, Austedo Xr |
| Merz North America, INC. | $279.00 | 2023 | Xeomin |
| Lundbeck LLC | $279.00 | 2020-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $270.65 | 2020-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $267.75 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $219.97 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $208.35 | 2019-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $188.01 | 2019-2024 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.61 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $79.91 | 2020-2021 | |
| Eisai INC. | $74.86 | 2020-2021 | |
| Almatica Pharma LLC | $63.80 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $42.79 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $38.32 | 2019 | |
| Neuronetics, INC. | $24.82 | 2019 | |
| Livanova USA, INC. | $19.57 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.